Drug Patent Watch
JULY 1, 2021
This chart shows the pharmaceutical companies with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 30, 2021
In line with the political objectives of the EU Green Deal, the program’s main goal is to fight climate change by establishing carbon farming practices at farmers’ level with benefits for the entire agricultural value chain / Program kicks off with over 25 farmers across seven countries in the EU and beyond: France, Spain, Belgium, Denmark, Germany, United Kingdom and Ukraine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JUNE 27, 2021
Happy 245th birthday, America! As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing. P.S.
Drug Patent Watch
JULY 2, 2021
Annual Drug Patent Expirations for NOXAFIL Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. It is available from three suppliers. There…. The post New patent for Merck Sharp drug NOXAFIL appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
JULY 2, 2021
This chart shows the pharmaceutical companies with the most film dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most film dosed drugs…. The post Which pharmaceutical companies have the most film dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JULY 2, 2021
Annual Drug Patent Expirations for INGREZZA Ingrezza is a drug marketed by Neurocrine and is included in one NDA. It is available from one supplier. There are fifteen patents protecting…. The post New patent for Neurocrine drug INGREZZA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 2, 2021
Annual Drug Patent Expirations for PERSERIS+KIT Perseris Kit is a drug marketed by Indivior Inc and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Indivior Inc drug PERSERIS KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2021
Annual Drug Patent Expirations for NATROBA Natroba is a drug marketed by Parapro Llc and is included in one NDA. It is available from two suppliers. There are two patents…. The post New patent expiration for Parapro Llc drug NATROBA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2021
Annual Drug Patent Expirations for LORBRENA Lorbrena is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for Pfizer drug LORBRENA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
JUNE 30, 2021
This chart shows the pharmaceutical companies with the most patents in Australia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Australia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for LEXETTE Lexette is a drug marketed by Mayne Pharma and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Mayne Pharma drug LEXETTE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for RHOPRESSA Rhopressa is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent for Aerie Pharms drug RHOPRESSA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for ROCKLATAN Rocklatan is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are eleven…. The post New patent for Aerie Pharms drug ROCKLATAN appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for NURTEC+ODT Nurtec Odt is a drug marketed by Biohaven Pharm and is included in one NDA. There are two patents protecting this drug. NURTEC ODT…. The post New patent for Biohaven Pharm drug NURTEC ODT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for TRIKAFTA+%28COPACKAGED%29 Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Vertex Pharms drug TRIKAFTA (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 30, 2021
Approval based on Phase 2 CheckMate -142 trial results showing nearly two-thirds of patients responded to the Opdivo plus Yervoy combination with durable responses observed. Opdivo plus Yervoy is the first dual immunotherapy regimen approved in the European Union for colorectal cancer. Opdivo plus Yervoy- based combinations now indicated in the European Union for five different advanced cancer types: mesothelioma, non-small cell lung cancer, melanoma, renal cell carcinoma and colorectal cancer.
The Pharma Data
JUNE 30, 2021
Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial to Test the Earlier Use of a CAR T-cell Therapy Against Standard of Care — — Study Met the Primary and Key Secondary Endpoints of Event-Free Survival and Objective Response Rate, Demonstrating a Highly Statistically and Clinically Significant Improvement Compared to Standard of Care — Kite, a Gilead Company (Nasdaq: GILD), today announced top-line results from the primary analysis of ZUMA-7, a
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Pharma Data
JUNE 30, 2021
he board of directors of Eli Lilly and Company (NYSE: LLY) (the “Board”) has declared a dividend for the third quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on September 10, 2021 to shareholders of record at the close of business on August 13, 2021. About Eli Lilly and Company?. Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.
The Pharma Data
JUNE 30, 2021
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their outstanding work into feline SARS-CoV-2 infections and feline leukaemia virus, respectively Boehringer Ingelheim has been sponsoring the award since 2008 to help foster talent development in the feline health research community Award represents important collaboration between Boehringer Ingelheim and the Advisory Board on Cat Diseases (ABCD).
The Pharma Data
JUNE 30, 2021
Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitors This analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 2021 1 EMPRISE data complement the landmark EMPA-REG OUTCOME
The Pharma Data
JUNE 30, 2021
Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis ® ) in Europe, Canada, Israel and global markets. TEL AVIV, Israel & ZURICH–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a biosimilar candidate to Lucentis ® (ranibizumab) in Europe, Canada
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
JUNE 30, 2021
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK). (“Takeda”) today announced new assignment of Directors. The details are as follows; Directors Who are Not Audit and Supervisory Committee Members. New assignment of Non-Audit and Supervisory Committee Directors effective June 29, 2021; Name Category Expected Role Christophe Weber Internal Existing Representative Director,President & Chief Executive Officer Masato Iwasaki Internal Existing Representative Director, Japan General Affair
The Pharma Data
JUNE 30, 2021
Takeda Pharmaceutical Company Limited (“Company”) announced today that after the Company withdraws the Shelf Registration Statement regarding the issuance of new shares filed on June 24, 2020, it will file a Shelf Registration Statement in Japan regarding the issuance of new shares. The purpose of the filing is to issue shares of common stock of the Company in a timely and flexible manner in association with the continued implementation of a Long Term Incentive Plan (“LTIP”).
The Pharma Data
JUNE 30, 2021
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: [link].
The Pharma Data
JUNE 30, 2021
– Significantly more upadacitinib-treated (15 mg or 30 mg, once daily) patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to patients on placebo at one-year (week 52) (p<0.001)[1] – All secondary endpoints were met, including the achievement of endoscopic improvement, HEMI and corticosteroid-free clinical remission at one-year (p<0.001)[1] – Safety results were consistent with the previous Phase 3 induction studies and the kno
The Pharma Data
JUNE 29, 2021
If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease. AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the DAPA-CKD Phase III
Expert insights. Personalized for you.
98 
Let's personalize your content